K Urakami, T Shimomura, T Ohshima, A Okada, Y Adachi, K Takahashi, M Asakura, R Matsumura
Division of Neurology, Faculty of Medicine, Tottori University, Yonago City, Japan.
Clinical neuropharmacology 1993 AugWe administrated WEB 1881, 800 mg/day (400 mg twice a day), nine patients with dementia of the Alzheimer type for 8 weeks, and undertook an open study to investigate the clinical effects of the distribution into the cerebrospinal fluid (CSF) as well as the influence on the neurotransmitter-related substances in the CSF. These were outpatients living at home with caregivers. Significant clinical improvement was shown by means of the Gottfries, BrĂ¥ne, and Steen Scale and by Hasegawa's dementia scale. Unchanged WEB 1881 was identified in the CSF. The mean concentration of which was 198.7 ng/ml, this corresponded to 19.0% of the plasma concentration. Of several neurotransmitter-related substances measured in the CSF, a marked rise of AChE activity was observed. Adverse effects consisted of a slight skin eruption in one case and alterations in a clinical laboratory test in another case. These were, however, not significant from a clinical viewpoint. It is suggested that the mechanisms of action of WEB 1881 are based on its transit into the CSF as well as the activation of intracerebral acetylcholinergic systems.
K Urakami, T Shimomura, T Ohshima, A Okada, Y Adachi, K Takahashi, M Asakura, R Matsumura. Clinical effect of WEB 1881 (nebracetam fumarate) on patients with dementia of the Alzheimer type and study of its clinical pharmacology. Clinical neuropharmacology. 1993 Aug;16(4):347-58
PMID: 8104098
View Full Text